Kishimoto Yoshimi, Saita Emi, Ohmori Reiko, Kondo Kazuo, Momiyama Yukihiko
Department of Food Science and Human Nutrition, Setsunan University.
Department of Food Culture, BAIKA Women's University.
Int Heart J. 2025;66(1):28-35. doi: 10.1536/ihj.24-407.
Atherosclerotic diseases, like coronary artery disease (CAD), are recognized to be associated with oxidative stress and inflammation. Sestrin2 is a stress-inducible protein that has anti-oxidant and anti-inflammatory properties. We previously reported that plasma sestrin2 levels were high in patients with CAD. However, no study has shown their prognostic value in patients with CAD. We investigated the association between plasma sestrin2 levels and major adverse cardiovascular events (MACE) (cardiovascular death, myocardial infarction, unstable angina, coronary revascularization, heart failure, or stroke) in 320 patients undergoing coronary angiography, of whom 191 had CAD. During a mean follow-up of 7.0 ± 4.2 years, 58 patients had MACE. Plasma sestrin2 levels were higher in patients with CAD than without CAD (median 16.4 versus 14.2 ng/mL, P < 0.05). Notably, patients with MACE had higher sestrin2 levels (19.5 versus 14.9 ng/mL) and more often had sestrin2 > 15.0 ng/mL (79% versus 49%) than those without MACE (P < 0.001). Kaplan-Meier analysis showed lower event-free survival in patients with sestrin2 > 15.0 ng/mL than in those with ≤ 15.0 ng/mL (P < 0.001). In multivariate Cox hazards analysis, sestrin2 level (> 15.0 ng/mL) was a significant predictor of MACE (hazard ratio: 2.44; 95%CI: 1.28-4.67), independent of CAD and atherosclerotic risk factors. Moreover, among 191 patients with CAD, sestrin2 level was also a significant predictor of MACE (hazard ratio: 2.51; 95%CI: 1.28-4.82), independent of the severity of CAD and coronary revascularization. Thus, high plasma levels of sestrin2 at baseline angiography were found to be associated with an increased risk of cardiovascular events in patients with CAD and patients undergoing coronary angiography.
动脉粥样硬化性疾病，如冠状动脉疾病（CAD），被认为与氧化应激和炎症相关。 sestrin2是一种应激诱导蛋白，具有抗氧化和抗炎特性。我们之前报道过CAD患者的血浆sestrin2水平较高。然而，尚无研究表明其在CAD患者中的预后价值。我们在320例行冠状动脉造影的患者中调查了血浆sestrin2水平与主要不良心血管事件（MACE）（心血管死亡、心肌梗死、不稳定型心绞痛、冠状动脉血运重建、心力衰竭或中风）之间的关联，其中191例患有CAD。在平均7.0±4.2年的随访期间，58例患者发生了MACE。CAD患者的血浆sestrin2水平高于无CAD患者（中位数16.4对14.2 ng/mL，P<0.05）。值得注意的是，发生MACE的患者sestrin2水平更高（19.5对14.9 ng/mL），且sestrin2>15.0 ng/mL的情况比未发生MACE的患者更常见（79%对49%）（P<0.001）。Kaplan-Meier分析显示，sestrin2>15.0 ng/mL的患者无事件生存率低于sestrin2≤15.0 ng/mL的患者（P<0.001）。在多变量Cox风险分析中，sestrin2水平（>15.0 ng/mL）是MACE的显著预测因子（风险比：2.44；95%CI：1.28 - 4.67），独立于CAD和动脉粥样硬化风险因素。此外，在191例CAD患者中，sestrin2水平也是MACE的显著预测因子（风险比：2.51；95%CI：1.28 - 4.82），独立于CAD的严重程度和冠状动脉血运重建。因此，发现在基线血管造影时血浆sestrin2水平高与CAD患者和行冠状动脉造影患者发生心血管事件的风险增加相关。
